Harnessing Natural Diversity to Probe Metabolic Pathways by Homann, Oliver R et al.
Harnessing Natural Diversity to Probe
Metabolic Pathways
Oliver R. Homann
1,2, Houjian Cai
3, Jeffrey M. Becker
3, Susan L. Lindquist
2*
1 Committee on Genetics, University of Chicago, Chicago, Illinois, United States of America, 2 Whitehead Institute for Biomedical Research, Cambridge, Massachusetts,
United States of America, 3 Department of Microbiology, University of Tennessee, Knoxville, Tennessee, United States of America
Analyses of cellular processes in the yeast Saccharomyces cerevisiae rely primarily upon a small number of highly
domesticated laboratory strains, leaving the extensive natural genetic diversity of the model organism largely
unexplored and unexploited. We asked if this diversity could be used to enrich our understanding of basic biological
processes. As a test case, we examined a simple trait: the utilization of di/tripeptides as nitrogen sources. The capacity
to import small peptides is likely to be under opposing selective pressures (nutrient utilization versus toxin
vulnerability) and may therefore be sculpted by diverse pathways and strategies. Hitherto, dipeptide utilization in S.
cerevisiae was solely ascribed to the activity of a single protein, the Ptr2p transporter. Using high-throughput
phenotyping and several genetically diverse strains, we identified previously unknown cellular activities that
contribute to this trait. We find that the Dal5p allantoate/ureidosuccinate permease is also capable of facilitating di/
tripeptide transport. Moreover, even in the absence of Dal5p and Ptr2p, an additional activity—almost certainly the
periplasmic asparaginase II Asp3p—facilitates the utilization of dipeptides with C-terminal asparagine residues by a
different strategy. Another, as-yet-unidentified activity enables the utilization of dipeptides with C-terminal arginine
residues. The relative contributions of these activities to the utilization of di/tripeptides vary among the strains
analyzed, as does the vulnerability of these strains to a toxic dipeptide. Only by sampling the genetic diversity of
multiple strains were we able to uncover several previously unrecognized layers of complexity in this metabolic
pathway. High-throughput phenotyping facilitates the rapid exploration of the molecular basis of biological
complexity, allowing for future detailed investigation of the selective pressures that drive microbial evolution.
Citation: Homann OR, Cai H, Becker JM, Lindquist SL (2005) Harnessing natural diversity to probe metabolic pathways. PLoS Genet 1(6): e80.
Introduction
Our understanding of the inner workings of eukaryotic
cells owes much to the yeast Saccharomyces cerevisiae. The
application of powerful genetic and molecular tools to this
model organism has yielded an extensively annotated
proteome. These analyses have beneﬁted greatly from the
engineering of experimentally tractable strains of S. cerevisiae,
but an unintended consequence of this focus has been a
tendency to ignore the vast wealth of natural genetic
variation found in diverse strains of this organism. Following
the ‘‘gold rush’’ ushered in by the sequencing of the S.
cerevisiae genome, efforts are being made to revisit this natural
diversity. Phenotypic analyses of diverse yeast strains [1,2] and
the application of microarray technology to the analysis of
allelic variation [3–8] and population genetic variation in
gene expression [9–11] are providing new insights into the
ecology and diversity of the species. Such analyses should also
be applicable to the elucidation of pathways that face strong
diversifying selection, such as those governing uptake and
metabolism of nutrients. As a test case, we employed high-
throughput phenotyping of diverse S. cerevisiae strains to
dissect the multiple activities contributing to the utilization
of di/tripeptides as a nitrogen source.
The capacity to import small peptides is a ubiquitous
cellular function, found in bacteria, fungi, plants, and animals
[12–16]. Although small peptides have clear nutritional value
as a source of amino acids, carbon, and nitrogen, they can
have additional beneﬁcial functions. For example, studies in
bacteria have demonstrated a link between peptide transport
and chemotaxis [17], sporulation [18,19], and the recycling of
cell wall peptides [20].
Peptide transport systems, however, can also be a source of
biological vulnerability. A variety of antimicrobial and
antifungal agents utilize the di/tripeptide transport machi-
nery to gain entry into the cell [21,22]. Thus, the beneﬁts and
risks associated with peptide import represent conﬂicting
evolutionary pressures that may help shape the regulation
and substrate speciﬁcity of peptide transporters. In a similar
vein, transporters of small peptides are also of great interest
for their medical applications, as routes for delivery of
peptidomimetic drugs [23,24].
Members of the PTR family of peptide transporters
transport a variety of substrates, including nitrates, amino
acids, and di/tripeptides [12,25]. All PTR members contain 12
predicted transmembrane helices, and transport a variety of
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many organisms, such as humans and plants, contain multiple
PTR2 family members, the yeast S. cerevisiae contains only one,
the di/tripeptide transporter Ptr2p.
The regulation of PTR2 expression in S. cerevisiae is strongly
inﬂuenced by the composition of the extracellular environ-
ment. PTR2 expression is induced in the absence of preferred
nitrogen sources [28]—even more so when the medium
contains particular amino acids [29]. Import of di/tripeptides
containing basic or bulky hydrophobic N-terminal residues
also induces PTR2 by reducing cellular levels of the PTR2
repressor Cup9p. Speciﬁcally, these di/tripeptides serve both
as ligands and as regulators of the E3 ubiquitin ligase Ubr1p,
which mediates a protein degradation system that is governed
by the identity of N-terminal amino acids [30,31] (Figure 1).
These peptides are too small to serve as targets for
degradation by the proteasome, and they are assimilated as
nutrients via other peptidases in the cells. However, di/
tripeptides with basic (Type 1: Arg, His, or Lys) and bulky
(Type 2: Ile, Leu, Phe, Trp, or Tyr) N-terminal residues can
compete with larger protein substrates for binding at the
Type 1 and Type 2 Ubr1p substrate-binding sites. Upon
binding, these peptides allosterically activate Ubr1p-medi-
ated degradation of Cup9p by release of the Ubr1p auto-
inhibitory domain, thus exposing a substrate-binding domain
that binds an internal degron in Cup9p [32]. Relief of Cup9p
repression of PTR2 results in enhanced PTR2 expression.
This initiates a positive regulatory feedback loop in which di/
tripeptide uptake perpetuates Ubr1p-mediated degradation
of Cup9p, up-regulation of PTR2, and additional di/tripep-
tide uptake [32–34].
Investigations of di/tripeptide import in S. cerevisiae have
typically been limited to the analysis of a small number of
substrates through complementation of auxotrophies or the
use of radiolabeled dipeptides. The development of the
Biolog (Hayward, California, United States) system of
Phenotype MicroArrays (PM) [35–37] provides the opportu-
nity to dramatically expand the scope of these analyses. The
PM system facilitates the classiﬁcation of bacterial and fungal
species by generating a characteristic phenotypic proﬁle,
which reﬂects the metabolic capabilities and chemical
sensitivities of different species. The strong representation
of peptides in the PM assay plates—284 of the 400 possible
dipeptide permutations and 11 tripeptides—provides a
unique opportunity to assay the capacity of different S.
cerevisiae strains to import and utilize dipeptides as nitrogen
sources.
Using high-throughput data from PM assays, we uncovered
extensive variation in dipeptide utilization in different
strains of S. cerevisiae. We exploited this variation to uncover
a diversity of strategies that may serve to balance the
opposing selection pressures of nutrient utilization and toxin
vulnerability. We ﬁnd that Ptr2p provides only one of at least
four distinct molecular activities that facilitate the utilization
of dipeptides in S. cerevisiae. The varying strengths of these
activities in different strains were key to their identiﬁcation.
No single strain would have revealed the full complexity of
dipeptide utilization, underscoring the importance of natural
genetic variation for developing a comprehensive under-
standing of cellular processes. We suggest that the compar-
Figure 1. Di/Tripeptide Uptake Is Enhanced by a Positive Feedback Loop
Governed by the N-End Rule Pathway
The E3 ubiquitin ligase Ubr1p contains binding sites for proteins
containing Type 1 (Arg, His, and Lys) and Type 2 (Ile, Leu, Phe, Trp, and
Tyr) N-terminal amino acids. In the absence of di/tripeptides, the PTR2
repressor Cup9p is abundant and PTR2 expression is minimal. Upon
binding of Type 1 and/or Type 2 di/tripeptides to Ubr1p, an auto-
inhibitory domain blocking the recognition of an internal Cup9p degron
dissociates from the Cup9p binding site, decreasing the half-life of
Cup9p (t ½) from approximately 5 min to less than 1 min. Consequently,
PTR2 repression is relieved and elevated levels of Ptr2p enhance di/
tripeptide uptake, initiating a positive feedback loop. This figure was
adapted from the diagram of Turner et al. [33], with the authors’
permission.
DOI: 10.1371/journal.pgen.0010080.g001
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Synopsis
Model organisms have allowed researchers to characterize basic
biological processes in exquisite detail. Homann et al. suggest that
this knowledge base presents a unique opportunity to exploit the
natural genetic variation found in diverse isolates of the same
species to gain new insights. Using high-throughput technology to
assay growth, Homann et al. found that laboratory strains, vineyard
isolates, and clinical isolates of the yeast Saccharomyces cerevisiae
exhibit very different capacities to utilize di/tripeptides as nutrient
sources. This led to the discovery of new di/tripeptide utilization
activities and an elaboration of their specificities. Variations in the
strength of these activities determine the spectrum of di/tripeptides
that are preferentially utilized in a given strain. In turn, this
influenced the vulnerability of these strains to a toxic peptide,
which exploits the transport machinery to gain entry into the cell.
This raises the intriguing possibility that opposing selective
pressures, in which the benefit of utilizing di/tripeptides as a
nutrient source is offset by the risk of importing toxic peptides, may
have shaped the observed natural diversity. The natural genetic
diversity present among isolates of model organisms augurs a rich
resource for revealing complexities in molecular pathways and
exploring the selective pressures that shaped them.ison of genetically diverse strains will provide many new
avenues for exploring the malleability of basic cellular
functions and the evolutionary mechanisms and selective
pressures that shape complex traits.
Results
To advance our understanding of the processes contribu-
ting to nitrogen utilization in S. cerevisiae, we studied a panel
of strains isolated from several widely differing growth
environments (Table 1). We included two related laboratory
strains, S288c and W303, two California vineyard isolates,
RM3 and RM8, a vineyard isolate thought to be of French
origin, Y55 [38], and a clinical isolate, YAT7. Because
expression of the dipeptide transporter PTR2 is strongly
induced by even micromolar amounts of certain amino acids
supplemented in the media [29], we ﬁrst restored all of these
strains to full amino acid prototrophy (see Materials and
Methods).
Assaying Nitrogen Source Utilization in Diverse Strains
Using PM Assays
We utilized the PM system to assay the ability of these
strains to utilize an extensive selection of dipeptides and
other compounds as nitrogen sources. Cells were grown in
96-well plates in which each well contained a different
nitrogen source. A proprietary tetrazolium dye solution,
which is reduced to the purple compound formazan, was
included in each well. Plates were photographed every 15
min, generating a growth curve for each well that primarily
reﬂected dye reduction [39]. The remaining growth signal was
attributable to turbidity resulting from cell growth.
Because the technology was developed for bacterial cells,
we ﬁrst asked how well the PM signal curves reﬂect yeast cell
growth and respiration, and how reproducible these pheno-
types were in standard yeast laboratory media. Reduction of
the tetrazolium dye ostensibly results from cellular respira-
tion [39], but when we tested petite strains of S. cerevisiae in
the PM assay, they remained capable of robust dye conversion
(data not shown). Thus, mitochondrial respiration is not
required to produce reductants for this dye. Next, we
employed dye-independent measures of growth, such as
measuring optical density of PM plates lacking the tetrazo-
lium dye and plating serial dilutions of cells from PM plates
to solid media to measure the number of colony-forming
units in each PM well. Dye conversion correlated well with
growth (see Materials and Methods), except that dipeptides
containing the amino acids histidine, lysine, and/or cysteine
sometimes caused dye reduction in the absence of growth
(data not shown). Interestingly, this growth-independent dye
reduction occurred only in the presence of cells. Since it
reﬂects an unknown metabolic process, these dipeptides were
omitted from our analyses. It should be noted, however, that
this growth-independent dye reduction exhibited strong
inter-strain variation, suggesting yet another source of
metabolic variation for further study.
The PM assay utilizes a viscous medium that supports less-
vigorous growth than typical laboratory media (data not
shown). To determine if growth on diverse substrates in PM
plates correlates well with standard laboratory media, we
assayed growth on dipeptides as the sole nitrogen source in
both solid and liquid standard media (see below), using
optical density at 600 nm to measure growth in the liquid
assays. Given the sensitivity of the dipeptide transport
machinery to environmental cues, it is unsurprising that
some differences were observed between these platforms. In
large part, however, these differing growth conditions
provided similar results, and the reproducibility on all tested
media was robust.
Shared Properties and Inter-Strain Variation in Nitrogen
Source Utilization
Next, we asked if the natural diversity in our yeast strains
produced phenotypic diversity in nitrogen source utilization.
The 48-h PM growth curves for each strain on each medium
are provided in the supplemental materials (Dataset S1–S3).
To simplify comparisons, each growth curve was assigned a
score reﬂecting the extent of growth, as shown for repre-
sentative curves in the legend of Figure 2 (see also Materials
and Methods). In agreement with an earlier study of the
ability of individual amino acids to serve as nitrogen sources
in S. cerevisiae [40], we found that cysteine, histidine, and lysine
did not support growth in any of our strains (Figure 2A).
These are the same amino acids that, when present in
dipeptides, caused some strains to reduce the tetrazolium dye
in the absence of growth. Apart from some inter-strain
variation in growth on glycine and tyrosine, the remaining
amino acids supported robust growth in all strains tested.
In contrast to the general uniformity in the utilization of
individual amino acids, the six strains we analyzed had very
different patterns of dipeptide utilization. To assist visual-
ization of the data, dipeptides were separated into two classes:
N-end rule dipeptides, which up-regulate PTR2 by enhancing
Ubr1p-mediated degradation of the Cup9p repressor (Figure
2B), and non–N-end rule dipeptides (Figure 2C). The clinical
isolate YAT7 utilized the broadest spectrum of dipeptides
(see Figure 2C in particular) and tripeptides (Figure 2D).
Indeed, it grew robustly on many peptides that none of the
other strains could utilize well, if at all. (Preliminary analyses
of two additional clinical isolates, YAT17 and YAT21, suggest
that robust di/tripeptide transport may be a common feature
of strains adapted to the atypical mammalian host environ-
ment; data not shown.) The laboratory strain W303 utilized
the fewest dipeptides. It lacked the broad capacity for N-end
rule dipeptide utilization characteristic of the other strains
(Figure 2B), but it did grow robustly on some of these
dipeptides. In contrast, growth of the French vineyard isolate
Y55 was limited on the non–N-end rule dipeptides in
Table 1. Strains Used in This Study
Strain
a Genotype Type Source(s)
W303-x MATa ura3 can1–100 ho Laboratory G. Fink/R. Rothstein
YAT7-x MATa ura3 ho::MX3 Clinical (peritoneal fluid) J. McCusker
RM8-x MATa ura3D0 ho::loxP Vineyard (California) B. Garvik/R. Mortimer
RM3-x MATa ura3D0 ho::loxP Vineyard (California) B. Garvik/R. Mortimer
S288c-x MATa ura3 ho Laboratory B. Garvik
Y55-x MATa ura3 ho::KAN-MX3 Vineyard (France) J. McCusker
YAT17-x MATa ura3 ho::KAN-MX3 Clinical (broncheolar) J. McCusker
YAT21-x MATa ura3 ho::KAN-MX3 Clinical (vaginal) J. McCusker
aWhen additional deletions were introduced into the strains, these modifications were appended to the strain name
(i.e., ‘‘x’’ represents ptr2D, cup9D, dal5D,o rptr2Ddal5D.)
DOI: 10.1371/journal.pgen.0010080.t001
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strain also exhibited a unique pattern in the utilization of
other nitrogen sources (Figure 2D and 2E).
Given the close relationship between W303 and S288c
(W303 was derived in part from crosses with S288c; R.
Rothstein, personal communication), it was surprising that
the PM proﬁles of S288c more closely resembled those of the
California vineyard isolates RM3 and RM8. However, S288c
and W303 did share two characteristics: Both grew robustly
on all of the dipeptides in the array that contained C-
terminal asparagine residues (Figure 2B and 2C, boxes with
red borders), and both grew well on D-asparagine (Figure 2E).
Overexpression of PTR2 Masks Inter-Strain Variation and
Enhances Di/Tripeptide Utilization
The diversity of dipeptide-utilization traits suggests pro-
found differences in the underlying mechanism of di/
tripeptide import among our conspeciﬁc strains. One likely
source of inter-strain variation in dipeptide utilization is
differences in PTR2 regulation. If dipeptide utilization is
limited by low levels of Ptr2p, up-regulation of PTR2 should
enhance growth. To determine how broadly a lack of PTR2
expression limits dipeptide utilization, we eliminated the
repressor of PTR2, Cup9p, in three strains whose wild-type
Figure 2. Variation in Nitrogen Source Utilization among Six Strains of S. cerevisiae
Each square represents the growth of one strain in the PM assay supplied with the indicated nitrogen source. The value reflecting the extent of growth
was generated from the 48-h signal curve of the PM assay and represented by the intensity of coloration, as shown in the legend. All signal values
exceeding 200 reflected very robust growth, and are therefore represented with the same color. Blue-bordered squares denote nitrogen sources that
produced varying results in that strain, exhibiting substantial variation in signal among replicates (r
2/mean .10 and at least one replicate with signal
.50 or ,200). Red-bordered squares denote putative substrates of the Asp3p asparaginase.
(A) Amino acids, (B) N-end rule dipeptides, (C) non–N-end rule dipeptides, (D) tripeptides; amino acids are represented as single letters, and (E)
miscellaneous nitrogen sources.
DOI: 10.1371/journal.pgen.0010080.g002
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weak: YAT7, RM8, and W303, respectively.
In all three strain backgrounds, the CUP9 deletions caused
robust growth on most of the di/tripeptides present in the
arrays (Figure 3). Even dipeptides that had not supported
growth in any of the wild-type strains, such as dipeptides
bearing the N-terminal acidic residues aspartate or gluta-
mate, supported growth upon deletion of CUP9 (Figure 3B).
Of the 197 dipeptides amenable to PM analysis, only a small
fraction—most notably Trp-Trp, Trp-Glu, Asp-Asp, and Pro-
Pro—supported little growth in the cup9D strains. These
dipeptides may either be refractory to transport or less
amenable to use as a nitrogen source following transport. The
robust dipeptide utilization phenotype of the cup9D mutants
indicates that Ptr2p is capable of transporting a very broad
array of di/tripeptides, a property that has long been assumed
but never addressed with such a large spectrum of dipeptides.
Further, the robust dipeptide-utilization phenotypes of the
cup9D mutant strains indicate that differences in regulatory
control of PTR2 are a key feature of the natural diversity
observed among the strain backgrounds. Whereas the wild-
type strains exhibited different dipeptide-utilization pheno-
types (see Figure 2B and 2C), relief of PTR2 repression by
deletion of CUP9 eliminated almost all inter-strain variation
(Figure 3). Thus, the limited capacity for dipeptide utilization
in wild-type W303 relative to RM8 and YAT7 is likely to
reﬂect a difference in PTR2 regulation rather than a
difference in Ptr2p function.
Ptr2p Is Not Required for the Utilization of Some
Dipeptides
The only known transporter of di/tripeptides in S. cerevisiae
is Ptr2p. Therefore, we expected that ptr2D strains would be
unable to utilize any di/tripeptides in the PM assay. Surpris-
ingly, this was not the case, particularly for non–N-end rule
di/tripeptides (Figure 3B and 3C). All three strains tested did
not require PTR2 to utilize a subset of these non–N-end rule
dipeptides. Indeed, the W303-ptr2D mutant grew just as well
as the wild-type strain on the non–N-end rule dipeptides.
When examined as a whole, these observations suggested
that at least two activities contribute to dipeptide utilization:
Ptr2p-mediated transport and an as-yet-unidentiﬁed activity.
For N-end rule dipeptides, Ptr2p was the main activity
contributing to their utilization, as evidenced by the almost
complete abrogation of growth on these nitrogen sources by
the ptr2D deletions (Figure 3A). For non–N-end rule di/
tripeptides, both Ptr2p and the Ptr2p-independent activity
played roles in their utilization (Figure 3B). The contribution
of Ptr2p to general dipeptide utilization varied from minimal,
as observed with W303, to substantial, as observed with the
clinical isolate YAT7 (Figure 3, compare wild-type and ptr2D
strains). In contrast, the similar growth properties of the
ptr2D strains suggested that the contribution of the Ptr2p-
independent activity was similar in all three strain back-
grounds.
Dal5p Confers a Ptr2p-Independent Dipeptide-Utilization
Activity
To identify the source of dipeptide utilization in the ptr2D
strains, we took advantage of the robust growth of the W303-
ptr2D strain when Ala-Leu was the sole source of nitrogen in
the PM assay. We speculated that the concentration of Ala-
Leu needed to support growth would be reduced if the gene
allowing its utilization was overexpressed. Accordingly, we
screened a high-copy (2 lm) genomic library for plasmids that
restored growth of W303-ptr2D on limiting quantities of Ala-
Leu (0.75 mM). After eliminating candidates that contained
the PTR2 open reading frame, the three remaining plasmids
were sequenced. Each plasmid carried the allantoate/ureido-
succinate permease gene DAL5.
To analyze the contribution of Dal5p to basal dipeptide
utilization, we constructed ptr2D, dal5D,a n dptr2Ddal5D
mutants in a variety of strain backgrounds. We began by
testing the growth of serially diluted cells on conventional
solid media containing different nitrogen sources (Figure 4).
These included the putative Dal5p substrate Ala-Leu, as well
as Tyr-Ala and Ala-Tyr, which had not supported growth of
the ptr2D mutant in any of the strains tested in the PM assay
(see Figure 3A and 3B). In all strains tested, the ptr2Ddal5D
double mutant abolished growth on all three assayed
dipeptide sources. Thus, utilization of these dipeptides
required one of these two systems.
In the case of the dipeptides Ala-Tyr and Tyr-Ala,
utilization was mediated by Ptr2p. Growth on these dipep-
tides was abolished by deletion of PTR2 alone, whereas
deletion of DAL5 alone had no apparent effect. In contrast,
the utilization of Ala-Leu involved both Ptr2p and Dal5p, but
the relative contributions of these two activities varied
between strains. Similar results were obtained using both
solid (Figure 4) and liquid media (2 mM Ala-Leu; Figure S1).
Ala-Leu could be utilized in strains RM8 and YAT7 via either
Ptr2p or Dal5p, but Ptr2p was necessary and sufﬁcient for
wild-type growth levels. Strains W303 and Y55 did not exhibit
this functional overlap in Ala-Leu utilization. W303-ptr2D
grew as well as wild-type W303 on Ala-Leu, but W303-dal5D
was completely unable to grow. In Y55, the same deletions
created the opposite effect: Y55-ptr2D could not grow,
whereas Y55-dal5D grew as well as wild-type Y55. Thus, Y55
relied upon Ptr2p for utilization of the assayed dipeptides,
whereas W303 relied predominantly on Dal5p.
The Scope of the Contribution of Dal5p to Di/Tripeptide
Utilization
Next, we used the PM assay to determine how many di/
tripeptides could be utilized as nitrogen sources through the
activity of the DAL5 gene. The gene was subcloned into a
clean 2-lm vector, from the original plasmid that was isolated
from the genomic screen, and tested in strain W303-ptr2D.
Unlike the effect of overexpressing PTR2 (in the cup9D
strain), the multi-copy DAL5 plasmid only enhanced growth
on a small number of di/tripeptides (Figure 5). With the
exception of Tyr-Gln, these di/tripeptides were all non–N-end
rule dipeptides. N-terminal alanine, glycine, and serine
residues were particularly favorable to Dal5p-mediated
growth.
To determine whether Dal5p activity was redundant or
supplemental to that of Ptr2p, the speciﬁc contribution of
Dal5p to di/tripeptide utilization was explored using PM
assays of the strains Y55-dal5D and RM8-dal5D (full data
presented in Figure S2). In the case of Y55, deletion of DAL5
had negligible impact upon dipeptide utilization (Figure S2B
and Figure 4). Because the strongest growth defect in wild-
type Y55 was in the utilization of those non–N-end rule
dipeptides that we have found to depend on Dal5p, we
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was veriﬁed by a PM assay of Y55-ptr2D. Unlike our earlier
assays of ptr2D mutants in YAT7, RM8, and W303, deletion of
PTR2 in Y55 completely eliminated growth on all dipeptides
and tripeptides (Figure S2). Thus, Y55 relies solely upon Ptr2p
for the transport of dipeptides.
In contrast, Dal5p contributed substantially to the utiliza-
tion of dipeptides in RM8. All of the dipeptides that
supported more robust growth in the presence of Dal5p
belonged to the non–N-end rule category, and the majority
contained the small N-terminal residues alanine or glycine
(Figure 6 and data not shown). Deletion of DAL5 in strains
RM8 and W303 did not signiﬁcantly affect the utilization of
any non-peptide nitrogen sources, except that growth was
eliminated on N-acetyl-L-glutamate, an intermediate in
arginine biosynthesis [41] (Figure S2C). (The fact that N-
acetyl-L-glutamate utilization is an indicator of Dal5p activity
explains why wild-type Y55 cannot utilize this substrate; see
Figure 2E.) Clearly, DAL5 makes an important contribution to
dipeptide utilization in yeast, and variations in DAL5 activity
contribute to the naturally occurring variation in nitrogen
utilization in diverse strains.
Elimination of Ptr2p and Dal5p Uncovers Additional
Dipeptide-Utilization Activities
To determine whether Ptr2p and Dal5p account for all
dipeptide utilization in the PM assays, we analyzed ptr2Ddal5D
double mutants in two strains: W303, which showed the
greatest dependence on Ptr2p-independent mechanisms, and
RM8, which relied heavily upon both Ptr2p and Dal5p (Figure
S2). In both strains, deletion of these two genes abolished all
growth on most tested dipeptides and tripeptides in both
strains. The most notable exception was that W303-
ptr2Ddal5D, but not RM8-ptr2Ddal5D, retained the capacity
to utilize all dipeptides with C-terminal asparagine residues
(Figure S2; boxes with red borders). The obvious candidate
for the underlying molecular determinant of this activity is
the periplasmic asparaginase II (see Discussion). Since this
protein is encoded by four copies of the ASP3 gene
interspersed among rRNA and Ty loci in the genome, the
origin of the phenotype was not amenable to genetic analysis.
A second strong exception to the requirement for Ptr2p
and Dal5 was the utilization of Met-Arg by RM8, which was
actually enhanced by the dal5D mutation (Figure 6) and
remained robust in the ptr2Ddal5D double mutant (Figure S2).
Figure 4. The Relative Contributions of Dal5p and Ptr2p to Dipeptide Utilization Vary among Strains of S. cerevisiae
Strains were cultured on YPD plates, as with the PM assays, and then suspended in water at a concentration of approximately 3.5 3 10
6 cells/ml and
plated as 13,5 3, and 253dilutions (from left to right). Each plate contained MM plus the nitrogen source indicated at the top of the column (with the
exception of the far right column, in which YPD plates were used). Plates were incubated at 30 8C for 4 d and then photographed. A Y55-ptr2Ddal5D
double mutant was not tested, since deletion of PTR2 alone was sufficient to eliminate dipeptide utilization.
DOI: 10.1371/journal.pgen.0010080.g004
Figure 3. Deletion of CUP9 and PTR2 Strongly Impacts Di/Tripeptide Utilization in S. cerevisiae Strains
Elimination of the PTR2 repressor Cup9p revealed that Ptr2p can facilitate the utilization of nearly all di/tripeptides tested in the PM assay, yet Ptr2p was
not required for the utilization of a subset of di/tripeptides as a nitrogen source. See Figure 2 for a detailed explanation of the yellow boxes and colored
borders.
(A) N-end rule dipeptides, (B) non–N-end rule dipeptides, and (C) tripeptides; amino acids are represented as single letters.
DOI: 10.1371/journal.pgen.0010080.g003
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and data not shown) indicated that the ability to robustly
utilize Met-Arg in the absence of Ptr2p and Dal5p function
was unique to RM8. Closer examination of the PM assay
plates revealed that this Ptr2p- and Dal5p-independent
activity might affect the utilization of other dipeptides as
well. When PM assay plates containing RM8-ptr2Ddal5D were
incubated at 30 8C for an additional 1 to 3 d following the PM
assay, growth was seen in wells containing other dipeptides—
speciﬁcally, those with C-terminal arginine residues (data not
shown). This delayed-growth phenotype did not require the
function of Dal5p or Ptr2p and was not observed in plates
containing either W303-ptr2Ddal5D or Y55-ptr2D. Thus, it
represented a fourth distinct dipeptide utilization activity.
Inter-Strain Variation in Sensitivity to the Toxic Dipeptide
Ala-Eth
The beneﬁt of efﬁcient utilization of di/tripeptides as a
nutrient source is likely to be counterbalanced by the
vulnerability associated with indiscriminate peptide trans-
port. To assay inter-strain variation in vulnerability to toxic
peptides, the panel of diverse S. cerevisiae strains was exposed
to a dipeptide containing L-ethionine (Eth), a toxic methio-
nine analogue (Figure 7). The purine derivative allantoin was
provided as a nitrogen source [42] to eliminate the nutri-
tional requirement for dipeptide uptake. Discs containing
different concentrations of Ala-Eth were applied to lawns of
cells, creating gradients of dipeptide concentration. Thus, the
diameter of the halo of growth inhibition surrounding a disc
is an indicator of dipeptide import.
In the standard halo assay, minimal medium with allantoin
(MMA) is supplemented with 30 lg/ml leucine to induce PTR2
expression (MMAþLeu medium). Under these conditions,
wild-type strains varied substantially in sensitivity to Ala-Eth
toxicity (Figure 7). S288c was the most sensitive to the
dipeptide, whereas W303 was completely resistant. In the
absence of the leucine inducer, only the clinical isolates
YAT17 and YAT21 were sensitive to Ala-Eth (Figure 7).
Deletion of PTR2 alone was sufﬁcient to confer complete
resistance to the toxic dipeptide under the conditions tested
(RM8-ptr2D and YAT7-ptr2D were tested; data not shown).
While this might suggest that Ptr2p is the primary transporter
of Ala-Eth, we note that Dal5p may also transport allantoin
[43,44], raising the possibility that allantoin competed with
Ala-Eth for Dal5p-mediated uptake. Indeed, Ala-Met, which is
structurally similar to Ala-Eth, supports growth in ptr2D
Figure 6. Deletion of DAL5 in Strain RM8 Strongly Affects the Utilization
of a Subset of Assayed Dipeptides
All instances in which RM8 and RM8-dal5D signal values differ by more
than 50 units and conform to our reliability criteria (see Figure 2) are
presented. Dipeptides followed by ‘‘(23)’’ are present in the PM assay
plates at twice the concentration of the other dipeptides.
DOI: 10.1371/journal.pgen.0010080.g006
Figure 7. Halo Assay for Uptake of the Toxic Ala-Eth Dipeptide
Cells were plated onto MMA with or without 30 lg/ml leucine, an
inducer of PTR2 expression. Halo diameters in the presence of discs
containing the indicated Ala-Eth concentrations are presented as the
mean 6 standard deviation. (ptr2D strains were also tested, and
exhibited no halos.)
aHalo boundary was indistinct, often slowly receding as cells closer to the
disc began to grow.
DOI: 10.1371/journal.pgen.0010080.g007
Figure 5. Utilization of a Subset of Dipeptides Is Enhanced in W303-
ptr2D upon Overexpression of DAL5
Strain W303-ptr2D was transformed with either the vector pRS426 or the
plasmid pRS426-DAL5,a2 - lm plasmid containing a genomic fragment
including DAL5, and phenotyped using the PM assay. The nitrogen
sources shown comprise all instances in which the signal values met our
reliability criteria (see Figure 2) and the presence of pRS426-DAL5 altered
the signal value by more than 50 units relative to the vector control.
Dipeptides followed by ‘‘(23)’’ are present in the PM assay plates at twice
the concentration of the other dipeptides.
DOI: 10.1371/journal.pgen.0010080.g005
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suggesting that Dal5p and Ptr2p both contribute to the
vulnerability of yeast cells to Ala-Eth.
Elimination of the PTR2 repressor Cup9p enhanced Ala-
Eth sensitivity in all strains tested, yet it also revealed
additional diversity among the strains (Figure 7, cup9D). The
resistance of strain W303 to Ala-Eth was overcome by the
cup9D mutation to the extent that the W303-cup9D mutant
exhibited higher sensitivity to Ala-Eth than cup9D mutants of
either RM8 or YAT7. All of the cup9D mutant strains
exhibited some sensitivity to Ala-Eth in the absence of the
leucine inducer. Curiously, despite the robust dipeptide
import characteristic of the YAT7 strain, YAT7-cup9D
produced much smaller halos under these conditions than
either W303-cup9D or RM8-cup9D (Figure 7; see also Figure 8).
Some of the inter-strain variation observed in the halo assay
might reﬂect varying sensitivity to ethionine. However, since
both changes in media composition and the cup9D mutations
affected strains differently, this diversity is clearly shaped by
the complex regulatory controls governing dipeptide import.
Expression and Localization of Ptr2p Varies Substantially
among Strains
Strain W303 was both highly resistant to the toxic Ala-Eth
dipeptide and limited in dipeptide utilization capacity.
Therefore, we asked whether PTR2 expression in this strain
differed from that of the other strains tested. To directly
visualize the expression of PTR2, a C-terminal FLAG-2xGFP-
6xHis tag was added to the endogenous PTR2 gene of strains
W303, RM8, and YAT7 by site-speciﬁc homologous recombi-
nation. These modiﬁed strains retained a similar capacity to
utilize dipeptides (data not shown). To facilitate comparison
of PTR2 expression with the results of the halo assay,
expression of green ﬂuorescent protein (GFP)-tagged PTR2
was assayed in a liquid version of the MMA and MMAþLeu
media, and ﬂuorescence was measured using a uniform
exposure level (Figure 8; halo assay images included for
comparison).
The presence of Ptr2p at the plasma membrane correlated
well with the extent of Ala-Eth toxicity observed in the halo
assay (except that ﬂuorescence was weaker in RM8 than might
have been expected from its strong Ala-Eth sensitivity in
MMAþLeu). In all other cases, conditions promoting strong
Ala-Eth sensitivity also induced strong PTR2 expression.
Strikingly, wild-type W303, which was resistant to Ala-Eth,
exhibited virtually no Ptr2p ﬂuorescence. The cup9D muta-
tion restored strong PTR2 expression and also restored Ala-
Eth sensitivity. Thus, the resistance of W303 to Ala-Eth in the
halo assay resulted from an absence of Ptr2p at the plasma
membrane. Moreover, these results conﬁrm that W303
contains a functional PTR2 gene subject to atypical regu-
lation.
Additional Aspects of PTR2 Regulation
Retrograde recycling of membrane-bound Ptr2p is thought
to represent an additional layer of regulatory control of
Figure 8. Inter-Strain Variation in PTR2 Expression and Sensitivity to the Toxic Dipeptide Ala-Eth
Media composition and the absence of Cup9p affect expression of GFP-tagged PTR2 and Ala-Eth toxicity. Three types of media were tested: MMA,
MMAþLeu, and YPD. ‘‘MMA’’ refers to minimal nitrogen medium containing 1 mg/ml allantoin as the nitrogen source. ‘‘þLeu’’ refers to the addition of
30 lg/ml leucine, an inducer of PTR2 expression. YPD is a standard rich S. cerevisiae medium; the presence of methionine precludes its use for the halo
assay. The left and right discs in each halo assay panel contained 0.1 lmoles and 0.2 lmoles of Ala-Eth, respectively. Microscopy was conducted using
cells grown to log phase in the indicated media. Three strains were imaged: W303, RM8, and YAT7. In each strain, the endogenous PTR2 gene contained
a C-terminal tag consisting of a FLAG epitope, two copies of GFP, and a 6xHis tag. The insets depict representative cells from the small subpopulation of
W303 cells that exhibited fluorescence.
DOI: 10.1371/journal.pgen.0010080.g008
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Although GFP-tagged Ptr2p was typically localized to the
membrane, when strain RM8 was grown in YPD, additional
ﬂuorescent signal was also observed in the vacuole and in
what appeared to be large vesicles. The high levels of PTR2
expression in the rich YPD media was itself surprising, since
PTR2 is thought to be subject to nitrogen catabolite
repression in the presence of preferred nitrogen sources
[28]. Although YAT7 also exhibited robust PTR2 expression
under these conditions, Ptr2p was conﬁned to the plasma
membrane. This inter-strain variation was likely inﬂuenced
by cellular Ptr2p levels, as cup9D mutants of RM8, YAT7, and
W303 all exhibited robust PTR2 expression and some intra-
cellular Ptr2p localization in YPD media (Figure 8). However,
although wild-type RM8 and YAT7 both exhibited strong
Ptr2p ﬂuorescence in YPD, only RM8 exhibited abundant
intra-cellular compartmentalization of Ptr2p, indicating that
retrograde transport of Ptr2p is yet another regulatory
process that varies between strains in S. cerevisiae.
The regulation of PTR2 in W303 differed signiﬁcantly from
the other strains analyzed in this study. Considering the
possibility that polymorphisms within the PTR2 promoter
region may account for the limited PTR2 expression in W303,
we sequenced an 889–base pair (bp) region immediately
upstream of the PTR2 start codon in the strains W303, S288c,
RM8, and YAT7 (Table S1). The promoter region in W303
differed from that of S288c at only one base, a C!T
transition at position  799. However, this polymorphism
was shared by the strain RM8, which unlike W303 is sensitive
to Ala-Eth and exhibits robust PTR2-dependent utilization of
N-end rule dipeptides. Thus, differences in promoter
sequence are not a likely source for the altered regulation
of PTR2 in W303.
Telomeric regions are common sites of epigenetic regu-
lation, and PTR2 is located in proximity (;50 kb) to a
telomere. In our analyses of GFP-tagged PTR2, a small
subpopulation (1 in 50 to 1 in 1,000, depending on
conditions) of strongly ﬂuorescent W303 cells was consis-
tently observed during growth in either the MMAþLeu
medium or in YPD (Figure 8; inset). W303 cells exhibiting
robust PTR2 expression also arose spontaneously at a high
frequency (.0.1%) on solid media. These cells maintain
competency for PTR2 expression following serial propaga-
tion on media that relieve selection for active dipeptide
transport (J. Manjrekar and S. Lindquist, personal communi-
cation). These switching events were far too frequent to
reﬂect mutation, suggesting that an epigenetic switch exists
that can stably confer competency for PTR2 expression in
W303 cells.
Discussion
Our results establish that the rich inter-strain diversity and
genetic tractability of S. cerevisiae can be combined with high-
throughput phenotyping to provide new insights into basic
cellular processes. Using this approach, we have uncovered
previously unrecognized functions and regulatory systems
governing the utilization of dipeptides as a nitrogen source.
The natural diversity in these systems included variation in
sensitivity to a toxic dipeptide, suggesting that dipeptide
utilization can be considered in the context of an adaptive
landscape shaped by opposing selective pressures.
Using High-Throughput Phenotyping to Study Di/
Tripeptide Utilization
The exploration of natural diversity using high-throughput
phenotyping techniques has the potential for tremendous
synergy with the existing high-throughput technologies that
have shaped our understanding of the cellular circuitry of S.
cerevisiae. The pursuit of an integrated understanding of yeast
functional genomics and proteomics (reviewed in [45]) has
been enabled by numerous powerful high-throughput ap-
proaches. For example, genetic networks have been eluci-
dated by high-throughput screens for synthetic lethality [46],
protein interaction networks have been mapped using mass
spectrometry [47,48], and transcriptional networks have been
elucidated by the now-ubiquitous technique of transcrip-
tional proﬁling using microarrays and by the mapping of
physical interactions between transcription factors and
promoters [49]. The technology for global analysis of growth
phenotypes remains largely underdeveloped and unex-
ploited—despite the fact that it is phenotype that determines
how cellular systems interface with selective pressures. Thus,
the broad synthesis of our understanding of genomic,
transcriptional, and phenotypic diversity is contingent upon
the development of robust technologies for high-throughput
phenotyping.
Here, we have tested one of the ﬁrst such systems by
assaying dipeptide and tripeptide utilization on a previously
unfeasible scale. The PM phenotypic assay allows simulta-
neous testing of approximately 2,000 growth conditions,
providing a tremendous savings in time and labor. The
technology was typically very robust and provided reliable
and reproducible data that were easily manipulated using the
accompanying software. However, the PM technology also has
several drawbacks that need to be addressed before this
technology is broadly suitable for use by the yeast research
community. Due to the initial design focus on generalized
bacterial phenotyping, many of the available PM assay plates
are not optimized for S. cerevisiae. Thus, the number of useful
growth conditions is considerably less than 2,000. This issue is
compounded by the high cost of the PM assay plates. Further,
different batches of media and PM assay plates provided by
the manufacturer often affected reproducibility. Such tech-
nical difﬁculties are not atypical for a new technology, and
the power of such tools in exploring the phenotypic diversity
of S. cerevisiae is clear. Hopefully, the importance of high-
throughput phenotyping will lead to reduced costs and
enhanced suitability of these technologies.
Uncovering Unexpected Complexity in Di/Tripeptide
Utilization
Through extensive phenotyping, we found that Ptr2p is but
one component of a multifaceted system in S. cerevisiae
governing the utilization of dipeptides as nitrogen sources.
The discovery of these additional components was made
possible by the dramatic inter-strain variation observed in
the contributions of these activities to dipeptide utilization
(summarized in Table 2). We have clearly identiﬁed one
previously unknown component of this system—the allan-
toate/ureidosuccinate permease Dal5p—and have deﬁned
parameters of two others that suggest mechanistic explan-
ations.
Of these four components, Ptr2p exhibits the broadest
dipeptide utilization activity. Relief of PTR2 repression by
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tripeptides tested. This was even true of W303, which
otherwise grew on only a limited subset of the N-end rule
dipeptides that supported growth of the other wild-type
strains. This restricted utilization of potential Ptr2p sub-
strates provides a window into the complex PTR2 regulatory
system. For example, one can ask why W303 is capable of
growing on Trp-Arg, but not Arg-Trp (see Figure 3A), even
though both are N-end rule peptides composed of identical
residues. One possibility is that the N-end rule pathway in
W303 is more responsive to Type 1 ligands (basic N-terminal
residues; e.g., Arg) than Type 2 substrates (bulky hydrophobic
N-terminal residues; e.g., Trp). Alternatively, substrate pref-
erence may arise from dipeptidase speciﬁcity [50] resulting in
more robust hydrolysis of Trp-Arg upon import. Although
beyond the scope of this analysis, additional insights and
hypotheses can be derived from the wealth of data provided
by our high-throughput analysis, and the approach developed
here—the application of a diverse panel of strains to the PM
assay to analyze di/tripeptide utilization—can be employed in
future studies to enrich our understanding of PTR2 regu-
lation and Ptr2p function.
Dal5p, a second component of the dipeptide utilization
system, was previously identiﬁed as a permease for the
pyrimidine biosynthetic precursor ureidosuccinate [51] and
the nitrogen source allantoate [43]. Expression of DAL5 is
subject to complex regulatory control by the nitrogen
catabolite repression system [43,52,53]. It is therefore ﬁtting
that Dal5p also is involved in the utilization of dipeptides as a
nitrogen source. With the exception of Tyr-Gln, all Dal5p di/
tripeptide substrates belonged to the non–N-end rule class.
Many of the dipeptides supporting growth in RM8-ptr2D (see
Figure 3) did not support growth in RM8-dal5D (see Figure 6).
Thus, Dal5p-mediated dipeptide transport is not redundant
to that of Ptr2p, but rather a complementary activity that
enhances the range of dipeptides that can be utilized.
A third component, evident in strains W303 and S288c,
governs the utilization of dipeptides containing C-terminal
asparagine residues as nitrogen sources (see Figure 2). Several
lines of evidence support the conclusion that the Asp3p
periplasmic asparaginase facilitates the utilization of these
substrates. Asp3p activity is closely linked to nitrogen
utilization. Nitrogen starvation has been demonstrated to
up-regulate ASP3 expression and promote the secretion of
asparaginase II [54]. Furthermore, the enzymatic activity of
asparaginase II hydrolyzes either L- or D-asparagine into
ammonia and aspartate, facilitating the use of D-asparagine
as a nitrogen source [55,56]. Of the strains tested, only W303
and the related laboratory strain S288c were able to utilize D-
asparagine in the PM assay (see Figure 2E). Genomic analyses
utilizing microarrays have noted a lack of detectable ASP3 in
Y55 [57] and a clinical isolate, YJM789 [3]. Neither Y55 nor
our clinical isolate, YAT7, were capable of utilizing the
putative Asp3p substrates (see Figure 2). Most important, the
asparaginase of the bacterial plant pathogen Erwinia caroto-
vora has been shown to deamidate C-terminal, but not N-
terminal, asparagine residues of small peptides [58]. This
speciﬁcity precisely matches the dipeptide utilization pheno-
types observed for W303 and S288c. Both strains are unable
to utilize the two dipeptides with N-terminal asparagine
residues present in the PM nitrogen plates (see Figure 2B),
but are able to utilize all dipeptides containing C-terminal
asparagine residues (see Figure 2; boxes with red borders). To
our knowledge, our study provides the ﬁrst evidence for such
an activity in S. cerevisiae, in which mechanisms of extrac-
ellular peptide processing are rare.
A fourth component of the dipeptide utilization system,
evident in strain RM8 but not W303, governs the use of
dipeptides containing C-terminal arginine residues, and Met-
Arg in particular. Utilization of Met-Arg is clearly enhanced
by deletion of DAL5 (see Figure 6) and persists in the
ptr2Ddal5D double mutant (Figure S2), and thus represents
another previously unrecognized mechanism of dipeptide
utilization. Given the speciﬁcity for a nitrogen-rich C-
terminal residue, an arginase activity comparable to the
asparaginase activity of Asp3p would seem a likely candidate.
Balancing the Benefits and Potential Risks of Robust Di/
Tripeptide Import
Variation in the relative strengths of the activities
contributing to dipeptide import can strongly impact the
range of dipeptide substrates utilized by the cell. Although di/
tripeptides can serve as a valuable source of nutrients,
evolutionary pressures opposing indiscriminate import may
reinforce mechanisms promoting transport speciﬁcity. One
such pressure might be the need to avoid import of antifungal
agents that exploit the di/tripeptide transport machinery to
gain entry into the cell (reviewed in [22]).
Of the di/tripeptide-utilization activities characterized in
this study, the Ptr2p transporter provides the means to
transport the broadest spectrum of dipeptide substrates (see
Figure 3), yet it is also the source of vulnerability to the toxic
Ala-Eth dipeptide (see Figure 7). Thus, strains that exhibit
robust PTR2 expression, such as the clinical isolate YAT7,
efﬁciently utilize a broad spectrum of dipeptides as a
nitrogen source (see Figure 2), but are also vulnerable to
Ala-Eth toxicity (see Figure 7). In contrast, the limited PTR2
expression in strain W303 provides protection from Ala-Eth
at the cost of a more limited capacity to utilize di/tripeptides.
However, in certain growth conditions, a fraction of W303
cells exhibit robust PTR2 expression, suggesting a possible
epigenetic mechanism for employing both high- and low-risk
di/tripeptide utilization strategies in an isogenic population.
The optimal strategy for dipeptide utilization will vary
between environments. For instance, in the presence of toxic
peptidomimetics that resemble Dal5p substrates, strain Y55
Table 2. Activities Contributing to the Utilization of Dipeptides
as a Nitrogen Source in Each Strain Background
Activity YAT7 RM3 RM8 Y55 S288c W303
Ptr2p Yes
a Yes Yes Yes Yes Yes
b
Dal5p Yes Yes Yes   Yes Yes
X-Asn
c        Yes Yes
X-Arg
d   ND yes   ND  
A qualitative summary of the contributions of the dipeptide utilization activities observed in this study; ‘‘yes’’
indicates activity is present; ‘‘ ’’, activity is minimal or absent; ‘‘ND’’, not determined due to insufficient data.
aPtr2p activity was exceptionally robust in this strain.
bPtr2p activity was limited in this strain.
cRefers to the putative Asp3p activity.
dRefers to the capacity to utilize dipeptides containing C-terminal arginine residues (particularly Met-Arg) in the
absence of Ptr2p and Dal5p activity.
DOI: 10.1371/journal.pgen.0010080.t002
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strains tested in this study, as it exhibits no detectable Dal5p
activity (Figure S2). In environments with a strong risk of
exposure to a variety of toxic di/tripeptides, the risks of
Ptr2p- and Dal5p-mediated import may outweigh the
potential nutritional beneﬁts. In such cases, the utilization
of a limited subset of di/tripeptides may represent a low-risk
mechanism by which some nutritional beneﬁt can be
extracted from the available di/tripeptides. For example,
extracellular release of ammonia from C-terminal asparagine
residues by Asp3p would serve as a more limited, but risk-
free, means of obtaining nitrogen from dipeptides. In
contrast, in an environment in which nitrogen sources are
scarce and the risk of importing toxic species is minimal,
robust expression of PTR2 would be a beneﬁcial trait. We
note that the clinical isolates YAT7 (see Figure 2), YAT17, and
YAT21 (data not shown) exhibit the most robust dipeptide
utilization of the strains studied, perhaps reﬂecting the
environmental pressures of the strains’ atypical growth
environment in the human host. Further investigation into
the ecology, population structure, and population genetics of
S. cerevisiae would beneﬁt future attempts to link phenotypic
diversity to likely environmental pressures.
High-throughput phenotyping and genetic diversity can
provide new insights into the genetic determinants governing
adaptation to the nutritional and chemical challenges of
diverse environments. Our study represents a ﬁrst-case
example of how this approach can be utilized to elucidate
metabolic processes and provide a broader evolutionary
context within which the observed natural diversity can be
considered.
Materials and Methods
Media and reagents. Synthetic deﬁned (SD), YPD, and 5-FOA
(BioVectra) media were made using standard formulations [59]. When
needed, G418 (Gibco, Carlsbad, California, United States) was added
to the YPD medium at 200 lg/ml to select for Kan
r. To select for
HygB
r, Hygromycin B (American Bioanalytical, Natick, Massachu-
setts, United States) was added to YPD at 250 lg/ml. All dipeptides
used outside of the PM assays were obtained from Bachem California
(Torrance, California, United States). A minimal medium (MM),
supplemented with the indicated nitrogen sources, was utilized for
the Bioscreen C growth curve assays (Growth Curves USA, Piscataway,
New Jersey, United States). MM contained 2% glucose, 0.17% yeast
nitrogen base without (NH4)2SO4 and amino acids (Qbiogene, Irvine,
California, United States), 18 mg/L uracil (omitted for URA3 plasmid-
bearing strains), and 2% agar (for solid media). The MMA used in the
halo and GFP assays was identical to MM, except that it contained 1 g/
l allantoin as a nitrogen source and a slightly different concentration
of uracil (20 mg/l). The Biolog PM media contained 50 mM glucose, 1
mM disodium pyrophosphate, 2 mM sodium sulfate, and a propri-
etary tetrazolium dye mix and IFY-0 medium. IFY-0 is a basal
medium, lacking nitrogen, carbon, phosphate, and sulfur sources,
which are supplemented as needed.
Plasmid construction. Construction of the pMS2 plasmid is
described in [60]. The plasmid pPTR2-2xGFP-SFH-KanR was con-
structed by addition of tandem copies of GFP (2xGFP) and a kan
r
selectable marker into plasmid pMS2. First, primers PTR2-FLAG-
GFP-F and PTR2-FLAG-GFP-R (all primer sequences are supplied in
Table S2) were used to amplify a 1.5-kb fragment containing 2xGFP
from plasmid pKW430 (a gift of Dr. Mary Miller, Rhodes University
[61]) and an additional 40 bp of ﬂanking sequence homologous to
pMS2. The plasmid pMS2 was then linearized at the unique
restriction site AgeI, located between the FLAG and His tags. 2xGFP
was then inserted between these two tags by homologous recombi-
nation, creating pMS4. A HincII fragment containing kanMX4 from
pFA6a-kanMX4 [62] was then inserted into the NaeI site of pMS4,
which lies beyond the stop codon following the 6xHis tag, creating
the ﬁnal pPTR2-2xGFP-SFH-KanR plasmid.
The plasmid pRS426-DAL5 was created by cloning an EcoRV
genomic fragment from a plasmid recovered in the genomic screen
(see below) into the 2-lm vector pRS426 (ATCC#77107; [63]). This
fragment spans a region from  1334 to þ2908, relative to the start
codon of the DAL5 gene.
pUG6-HygB was created by replacement of the kanMX marker in
pUG6 [64] with a hphMX cassette from pAG32 [65]. First, a PCR
fragment containing the hphMX cassette was ampliﬁed from pAG32
using primers O-199 and O-200 and digested with MluI and BsmI.
The resulting fragment was then inserted into the similarly digested
pUG6.
Strain construction. The source and origins of the strains used in
this study are indicated in Table 1. To make all strains MATa ura3,
some modiﬁcations were made to eliminate amino acid auxotrophies,
mutate URA3, and change mating types (described in detail in
Protocol S1). All transformations were conducted using the standard
lithium acetate technique [66].
PTR2 was deleted with a short-ﬂanking homology (SFH) cassette
ampliﬁed from plasmid pFA6a-GFP(S65T)-kanMX6 [62] (pAG32 [65]
in the case of Y55; the GFP portion of the plasmid was not ampliﬁed).
This deletion cassette replaced the PTR2 region spanning þ77 to
þ1781, relative to the start codon, with a kanMX marker (hphMX in
the case of Y55). CUP9 was deleted with a SFH cassette ampliﬁed from
plasmid pFA6a-GFP(S65T)-kanMX6, removing the CUP9 region
spanning þ41 to þ878, relative to the start codon. DAL5 was deleted
with a hphMX marker from a SFH cassette ampliﬁed from pAG32.
This deletion cassette eliminated the DAL5 region spanning  70 to
þ1594, relative to the start codon.
Addition of a FLAG-2xGFP-6xHis tag to the C-terminus of
endogenous PTR2 was accomplished with a SFH cassette ampliﬁed
from plasmid pPTR2-2xGFP-SFH-KanR. Proper integration was
ensured by selection on G418 media and veriﬁcation by colony
PCR. Final conﬁrmation of proper integration was obtained by
observation of membrane-localized GFP ﬂuorescence in MMAþLeu
medium.
PM assays of nitrogen source utilization. A full list of the nitrogen
sources tested in the PM assay plates is provided in Dataset S4. Each
well of the PM plates contains a very low micromolar amount of
amino acids, at a level insufﬁcient to complement auxotrophies or
serve as an adequate nitrogen source. All dipeptides are present at
the same concentration (between 1–4 mM, the precise concentration
is proprietary information), with the exception of the small set of
dipeptides present in PM03, which are present at double the
concentration of the others. (These are notated as (2x) when
presented in the ﬁgures.)
Strains were prepared for inoculation into the PM assay plates as
follows. Glycerol stocks were streaked to YPD plates and incubated at
30 8C for approximately 48 h. Next, two to three colonies from each
strain were restreaked to one section of a fresh YPD plate and
incubated overnight at 30 8C. In the morning, cells on each YPD plate
were spread over the plate to form a thin layer and incubated an
additional 4–6 h to ensure that most cells were actively growing. This
technique also served to avoid the late-growth clumping encountered
with some wild strains. In the case of strains containing plasmids,
standard SD–ura dropout plates were used in place of YPD.
Cells were then inoculated into sterile water in 20 3 100 mm test
tubes and adjusted to a transmittance of 63% (;5310
6 cells/ml). This
483 concentration cell suspension also contained 14.4 mM uracil,
except when plasmids were used. The cell suspension was then
reduced to 13 concentration by dilution into the Biolog PM media;
100 ll of this mix was then inoculated into each well of the PM assay
plates PM03, PM06, PM07, and PM08. The plates were then sealed
with sterile Axygen SealPlate ﬁlm (Union City, California, United
States), placed in the OmniLog reader (Biolog), and incubated for 48
ha t3 08C. The OmniLog reader photographs the plates at 15-min
intervals, converting the pixel density in each well to a signal value
reﬂecting cell growth and dye conversion.
After completion of the run, the signal data were compiled and
analyzed. Signal data were exported from the Biolog software,
compiled using Microsoft Excel (Redmond, Washington, United
States), and then visually represented using Java TreeView v1.0.8
[67] and Adobe Illustrator (San Jose, California, United States). We
chose to export the average and maximum signal value for each well
and then average the two values. In doing so, we were able to
represent the full time course by a single number and weight the
value towards latter time points. Shadows cast over perimeter wells in
the OmniLog machine sometimes raised the basal signal level of these
wells. This was accounted for by determining a ‘‘baseline’’ signal level
for each well by calculating the average signal level for the ﬁrst 2 h of
the run. This value was then subtracted from the previously
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can be summarized as follows:
Signal value¼([average signal over 48 hþmaximum signal over 48 h]/
2)   (average signal over ﬁrst 2 h)
In all cases, a minimum of two replicate PM assay runs were
conducted, and the average of the signal values was used. Addition-
ally, when non–wild-type strains were assayed, two independently
constructed deletion strains were always tested. The PM assay data
used to calculate the signal values presented in this study are
provided in Dataset S4. Images of all signal curves are provided in
Datasets S1–S3.
To ensure that dye reduction was not occurring in the absence of
growth, all PM plates were carefully examined following each run.
The plates were inverted upon a light-box such that cells were visible
in wells that supported growth. This approach revealed that
dipeptides containing lysine, histidine, and cysteine residues, as well
as the amino acid histidine, sometimes supported reduction of the
dye in the absence of growth. (Dipeptides containing these residues
were omitted from the analysis; see Results.) Two additional control
measures were taken to ensure that the correlation between dye
reduction and cell density was robust. First, the PM assay was
conducted once with each wild-type strain in the absence of the
tetrazolium dye. Second, several PM runs were plated as dilution
series to YPD media at the conclusion of the 48-h run. These
additional measures conﬁrmed that, with the exceptions noted above,
the PM assay signal is a reliable indicator of growth in the presence of
the nitrogen sources discussed in this study.
Bioscreen growth curve analysis. A selection of PM assay
dipeptide-utilization phenotypes were veriﬁed using a Bioscreen C
(Growth Curves USA) plate reader. Strains were cultured as described
for the PM assay, but were inoculated at an optical density at 595 nm
(OD595) of 0.02 into MM supplemented with the indicated nitrogen
source. The mixture was inoculated into a 100-well plate and
incubated in the Bioscreen C at 30 8C with heavy shaking. Measure-
ments of OD600 were made at 45-min intervals. Each growth curve was
conducted in duplicate wells and was repeated at least once.
Screen for Ptr2p-independent dipeptide utilization. The screen was
conducted using a pRS202-based genomic library (2 lm; URA3)
containing Sau3AI-digested genomic DNA with an average insert size
of 6–8 kb (gift of Dr. Gerald Fink; originally constructed by Connelly
and Hieter from a strain congenic with S288c [68]). A full description
of the screen can be found in Protocol S2.
Halo assay of Ala-Eth toxicity. The sensitivity of deletion mutants
to the toxic dipeptide Ala-Eth was measured as previously described
[29]. Ethionine (Eth) is an analog of methionine, and utilization of Eth
causes cell death. The tested strains were grown overnight in MMA.
Yeast cells were harvested and washed three times with sterile,
distilled water, then counted and adjusted to 5310
6 cells/ml. One ml
of the cell suspension was added to 0.8% noble agar (3 ml) and plated
onto MMA with or without leucine (30 lg/ml), an inducer of PTR2
expression. Four 6-mm sterile paper disks containing either 0.2, 0.1,
0.05, or 0.025 lmoles of Ala-Eth were placed on the lawn of cells. The
size of the halo was measured after two days of incubation at 30 8C.
Between two and four replicates were conducted for each assay.
Although strains Y55 and RM3 were unable to utilize allantoin in the
PM assay (see Figure 2E) and in additional Bioscreen C assays using
liquid medium (0.5 mM allantoin; data not shown), both strains were
capable of utilizing allantoin in the solid halo assay medium.
Sequencing upstream of PTR2. Although the region comprising the
PTR2 promoter has yet to be clearly deﬁned, the sequenced span, an
889-bp region immediately upstream of the PTR2 start codon, should
contain the key regulatory elements. The region bound by the Cup9p
repressor has been narrowed to the region spanning  897 to  448
[34], relative to the PTR2 start codon. In addition, a predicted amino
acid–dependent upstream activator sequence (UASAA) is located
between  777 and  760 [69]. Genomic DNA was prepared using the
‘‘smash and grab’’ technique [70]. A 927-bp fragment containing the
desired sequence was ampliﬁed with primers O-321 and O-324, using
an equal amount of Taq and Vent polymerases. Each reaction mix
was split into eight aliquots and repooled following ampliﬁcation.
This approach was taken to help control for the possibility that a
single replication error could propagate through the entire sample.
PCR products were then puriﬁed with a Qiagen PCR puriﬁcation kit
(Valencia, California, United States) and sequenced in both direc-
tions by Northwoods DNA Inc. (Solway, Minnesota, United States)
using oligos O-321, O-322, O-323, and O-324. Sequencing data were
analyzed using Sequencher DNA sequencing software (Gene Codes
Corporation, Ann Arbor, Michigan, United States).
GFP microscopy. To test the localization of GFP-tagged Ptr2p,
yeast strains carrying PTR2 with a C-terminal FLAG-2xGFP-6xHis tag
were grown at 30 8C in MMA, MMAþLeu, or YPD media. Yeast cells
were collected during log-phase and imaged. The GFP signal was
observed by ﬂuorescence microscopy with a 470–490-nm excitation
wavelength and 515-nm emission ﬁlter ﬁtted to an Olympus micro-
scope (Melville, New York, United States). Both ﬂuorescent and
differential interference contrast (DIC) images were taken with a
MicroFire camera (Model S99809; Olympus).
Supporting Information
Dataset S1. PM Signal Curves for Data Presented in Figure 2
Each image provides the signal curves generated by the OmniLog
software in each well of the four 96-well plates that constitute the PM
nitrogen source utilization assay (see Dataset S4 for full listing of
plate contents). The x-axis of each signal curve represents the 48-h
time course. The y-axis represents the signal intensity, an indirect
measure of growth. The different colored lines used for the signal
curves represent independent replicates of the PM assay.
Found at DOI: 10.1371/journal.pgen.0010080.sd001 (2.1 MB DOC).
Dataset S2. PM Signal Curves for Data Presented in Figure 3
See Dataset S1 legend for details.
Found at DOI: 10.1371/journal.pgen.0010080.sd002 (2.2 MB DOC).
Dataset S3. PM Signal Curves for Data Presented in Figure S2
See Dataset S1 legend for details.
Found at DOI: 10.1371/journal.pgen.0010080.sd003 (3.1 MB DOC).
Dataset S4. Raw Quantitative PM Data
Contains data used to calculate signal values and a complete listing of
the contents of the PM plates utilized in this study.
Found at DOI: 10.1371/journal.pgen.0010080.sd004 (805 KB XLS).
Figure S1. Dal5p and Ptr2p Exhibit Strain-Dependent Contributions
to the Utilization of Ala-Leu as a Nitrogen Source
Wild-type, dal5D, ptr2D, and ptr2Ddal5D versions of the indicated
strains were grown at 30 8C in liquid MM containing 2 mM Ala-Leu as
the sole nitrogen source. A few time points were omitted because of
technical difﬁculties with the Bioscreen C growth curve machine.
Found at DOI: 10.1371/journal.pgen.0010080.sg001 (2.8 MB JPG).
Figure S2. Additional PM Signal Proﬁles Reveal the Varied
Contribution of Dal5p to Di/tripeptide Import in Strains RM8,
W303, and Y55
Refer to Figure 2 for details on data analysis and presentation. The
column label ptr2D (vector) refers to strain W303-ptr2D transformed
with the high-copy (2 lm) vector pRS426. The column label ptr2D
(DAL5) refers to strain W303-ptr2D transformed with plasmid
pRS426-DAL5. Note that the PM assays presented in this ﬁgure
utilized a more recent manufacturing lot of the PM nitrogen plates
than those presented in the other ﬁgures. Different lots can produce
subtle differences in signal magnitude. The wild-type RM8 and Y55
PM data presented here were derived from the same lot to facilitate
direct comparison.
Found at DOI: 10.1371/journal.pgen.0010080.sg002 (631 KB PDF).
Protocol S1. Construction of the Strains Used in This Study
The source and origins of the strains used in this study are indicated
in Table 1.
Found at DOI: 10.1371/journal.pgen.0010080.sd005 (39 KB DOC).
Protocol S2. Screen for Ptr2p-Independent Dipeptide Utilization
Found at DOI: 10.1371/journal.pgen.0010080.sd006 (25 KB DOC).
Table S1. Polymorphisms in the Region Upstream of PTR2, Relative
to the Standard S288c Sequence
Found at DOI: 10.1371/journal.pgen.0010080.st001 (28 KB DOC).
Table S2. Oligos Used in This Study
Found at DOI: 10.1371/journal.pgen.0010080.st002 (52 KB DOC).
Accession Numbers
The Swiss-Prot (http://www.ebi.ac.uk/swissprot) accession numbers for
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High-Throughput Phenotyping and Diversitythe genes and gene products discussed in this paper are ASP3
(P11163), Cup9p (P41817), DAL5 (P15365), Ptr2p (P32901), and Ubr1p
(P19812).
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